English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMalignant mesothelioma is a very aggressive cancer with a very poor survival and limited treatment options. Thus, a deeper knowledge of the mechanisms modulating mesothelioma initiation and progression is critical for novel therapeutic strategies.
Tag: Mesothelioma
New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial
An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.
March Tip Sheet From Sylvester Comprehensive Cancer Center
A new study reported in JAMA Network Open unveils disparities in Mesothelioma survival, a grant to help construction workers nail quitting smoking, a new AI algorithm that offers insights into deadly cancer, a newly launched Neuroendocrine Tumors Program, a cancer researcher chosen to co-lead Tumor Biology Program and more are in this month’s tip sheet from Sylvester Comprehensive Cancer Center.
Are the Benefits of New Cancer Drugs Worth the Cost?
An international research group including scientists from Italy, the United States, Ireland, and Israel have published a three-year analysis of the Mesothelioma (Me) drug trial, Check-Mate 743 (CM-743).
Cellular Cilium an Early Sign of Mesothelioma Differentiation
A new study investigated the expression of the primary cilium in mesothelioma, finding that primary cilia is preferentially lost in the more aggressive subtype of mesothelioma and further research may confirm its potential prognostic and diagnostic value.
Drug Repurposing Identifies New Candidates to Treat Mesothelioma
A group of researchers, led by Antonio Giordano, M.D., Ph.D., Director and Founder of the Sbarro Health Research Organization (SHRO), Temple University, in collaboration with Stefano Landi, Ph.D.,. Chair of Genetics at University of Pisa, Italy, have identified potential novel drug candidates for the treatment of Malignant Pleural Mesothelioma (MPM).
Immunotherapy-Chemotherapy Treatment Coupled with In-Depth Genomic Analyses Leads to Improved Survival for Patients with Mesothelioma
Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Exploring PD-L1 Expression in Malignant Peritoneal Mesothelioma
In a recent study from Rutgers Cancer Institute of New Jersey, researchers tested whether or not mesothelioma cancer cells express high amounts of PD-L1, a protein that is abundantly present on some types of cancer cells. The PD-L1 protein is an inhibitory molecule that binds to the PD-1 receptor on T-cells, which are cells known to have the ability to recognize and destroy cancer cells in the body. Results of the work are being shared as a poster presentation at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care virtual meeting.
Getting Basic Research from the Lab to Independent Clinical Trials, Especially in Rare Cancers Like Mesothelioma
On the 18th and 19th of February, Sbarro Health Research Organization (SHRO) Founder and Director, Antonio Giordano, M.D., Ph.D., will host an online medical conference titled, “Why do we need independent research in oncology?”
How a Mesothelioma Patient Stays in the Game
It started on the tennis court, in 2016. A lunge for the ball, an awkward fall, and then sore ribs with subsequent backhands. At least that’s what Martin Snyder thought was the cause of his pain. He was wrong. An X-ray and further imaging over the ensuing weeks revealed that the slim and fit psychotherapist, then 73, had mesothelioma, a rare cancer usually caused by asbestos exposure.
Biomarker Candidates to Revolutionize Earlier Diagnosis of Mesothelioma
Mesothelioma is a deadly cancer mainly caused by exposure to asbestos fibers.
Despite Promising Lab Results, Most Precision Medicine Therapies for Mesothelioma Fail in the Clinical Setting
Malignant mesothelioma (MM) is a lethal cancer mainly caused by exposure to asbestos, for which, unfortunately, no current treatment has proven effective, despite the identification of several promising therapeutic targets over the years.
Research News Tip Sheet: Story Ideas from Johns Hopkins Medicine
Research news from Johns Hopkins Medicine.
Breaking Research News from Annual Meeting of American Society of Clinical Oncology
Johns Hopkins Kimmel Cancer Center thoracic cancer and cancer genomics experts reported promising new findings and studies in mesothelioma, lung cancer and melanoma at the annual meeting of the American Society of Clinical Oncology (ASCO), the world’s leading professional organization for physicians and oncology professionals caring for cancer patients.
Researchers Silence PRMT5 Gene to Slow Mesothelioma Using Precision Medicine
Silencing of the protein coding gene PRMT5 has possible therapeutic potential for treating Mesothelioma (MM), according to a recent in vitro study published in the Journal of Cellular and Molecular Medicine.